Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461713 | 0.86 | HTR6 (0.51) | HTR6 | |
| SCHEMBL25420439 | 0.86 | HTR6 (0.51) | HTR6 | |
| SCHEMBL13051118 | 0.83 | HTR6 (0.52) | HTR6PDPK1METLMNASMN1; SMN2 | |
| SCHEMBL5350219 | 0.82 | HTR6 (0.64) | HTR6LMNASMN1; SMN2HTR1ADRD2 | |
| SCHEMBL30975059 | 0.75 | HTR6 (0.61) | HTR6 | |
| SCHEMBL30974768 | 0.74 | HTR6 (0.59) | HTR6LMNASMN1; SMN2HTR1ADRD2 | |
| SCHEMBL2110801 | 0.74 | HTR6 (0.49) | HTR6BRD4LMNASMN1; SMN2HTR2A | |
| SCHEMBL21805760 | 0.74 | AKR1C3 (0.49) | HTR6BRD4LMNASMN1; SMN2HTR2A | |
| SCHEMBL29247367 | 0.74 | HTR6 (0.59) | HTR6LMNASMN1; SMN2HTR1ADRD2 | |
| SCHEMBL17097143 | 0.74 | HTR6 (0.56) | HTR6LMNASMN1; SMN2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133074-A2 | 7-AZAINDOLE DERIVATIVES | Merck Patent GmbH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2670748-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-28 | — | — | EP | disclosed |
| CN-105732617-A | 7-azaindole derivatives | 默克专利股份公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-102958930-A | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | MERCK PATENT GMBH | 2013-03-06 | — | — | CN | disclosed |
| WO-2012104007-A2 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-08-09 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511056-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080262004-A1 | Tgf-Beta Inhibitors | ELI LILLY AND COMPANY (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1812450-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052568-A2 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262004-A1 | Tgf-Beta Inhibitors | TGFB1, TGFBR1, TGFB2 | HTR6 3912/4885PDPK1 2667/4885MET 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.